Myriad Genetics, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has announced an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud. This investigation follows a significant 41.3% drop in Myriad's stock price on May 7, 2025, after the company reported a 3% year-over-year decline in total revenue and a 20% drop in pharmacogenomics revenue due to reduced coverage by UnitedHealthcare. The firm is encouraging affected investors to contact them to discuss legal options for recovering losses.
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
This article analyzes the Q4 earnings of Myriad Genetics (NASDAQ:MYGN) and compares its performance with other therapeutics stocks. While the therapeutics sector saw strong revenue beats collectively, individual stock performances varied. Myriad Genetics exceeded expectations with flat year-on-year revenue and strong full-year EBITDA guidance, showcasing positive momentum in key testing areas.
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
This article analyzes the Q4 earnings across various therapeutics stocks, spotlighting Myriad Genetics' performance relative to its peers. Myriad Genetics (MYGN) exceeded analyst expectations with flat year-on-year revenue but strong full-year EBITDA guidance, driven by growth in cancer and mental health testing. The piece also reviews the results of Novavax (NVAX), United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV), highlighting their revenue performance, market reactions, and key business developments.
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y
Myriad Genetics (NASDAQ: MYGN) saw its shares jump by 12% following a better-than-expected fourth-quarter performance, with adjusted earnings per share and revenue both surpassing analyst estimates. The company provided optimistic first-quarter revenue guidance, projecting a 2%–4% year-over-year increase, and reiterated its full-year 2024 revenue and earnings forecasts. This positive outlook signals confidence in continued growth and operational efficiency.
Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings
The Vanguard Group filed Amendment No. 14 to its Schedule 13G/A for Myriad Genetics Inc. (MYGN), reporting that it beneficially owns 0 shares, representing 0% of the common stock. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their beneficial ownership separately. The filing clarifies that while Vanguard Group itself no longer holds beneficial ownership, its subsidiaries continue to pursue the same investment strategies.
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts
Myriad Genetics (NASDAQ:MYGN) has received a consensus "Hold" rating from analysts, with an average 12-month price target of approximately $8.94. The company recently saw notable insider buying, including purchases by a director and the CEO, totaling 144,507 shares worth $694,548 in the last quarter. Despite reporting a quarterly EPS beat of $0.04 and $209.8M in revenue, the stock traded down to $4.45, reflecting a negative net margin and expectations of a negative EPS for the current year.
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y
Myriad Genetics stock saw a significant jump after the company reported strong fourth-quarter results, beating analyst expectations. The company also provided an optimistic outlook for the first quarter, projecting a year-over-year revenue increase of 2%–4%. This positive financial update has likely contributed to the positive market reaction.
Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes
Myriad Genetics' Chief Operating Officer, Mark Verratti, had 2,055 shares of common stock withheld to satisfy tax obligations related to the vesting of restricted stock units. This routine tax-related transaction occurred on March 22, 2026, with shares valued at $4.58 each based on the March 20, 2026 closing price. Following this withholding, Verratti directly owns 630,715 shares of Myriad Genetics Common Stock.
Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes
Myriad Genetics' Chief Scientific Officer, Dale Muzzey, had 2,019 shares of MYGN common stock withheld by the company on March 22, 2026, to cover tax obligations arising from the vesting of restricted stock units. This transaction, valued at $4.58 per share, was a tax-withholding disposition and not an open-market sale. Following this, Muzzey directly holds 327,256 shares, indicating a minor adjustment to his overall equity.
Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding
Myriad Genetics CFO Benjamin Richard Wheeler had 549 shares of common stock withheld by the company to cover tax obligations related to restricted stock unit vesting. The shares were valued at $4.58 each based on the closing price on March 20, 2026, and this was an administrative tax withholding, not an open-market sale. Following this transaction, Wheeler directly holds 298,509 shares of Myriad Genetics common stock.
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 1000
Myriad Genetics, Inc. (NasdaqGS: MYGN) has been dropped from the S&P 1000 index, as well as the S&P 600 CI and S&P Composite 1500 CI. This news comes alongside recent updates including FDA approval for its MyChoice as a companion diagnostic for an ovarian cancer drug, and insider trading activity. The company specializes in genetic testing and precision medicine, focusing on Oncology, Women's Health, and Mental Health.
Myriad Genetics, Inc.(NasdaqGS:MYGN) dropped from S&P 600 Health Care
Myriad Genetics, Inc. (NasdaqGS:MYGN) has been removed from the S&P 600 Health Care index. The company specializes in genetic testing and precision medicine, offering tests for oncology, women's health, and mental health. Recent news includes FDA approval for its MyChoice CDx as a companion diagnostic for an ovarian cancer drug, and insider share purchases.
MYGN Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for MYGN, including past performance, future forecasts, and stock price reactions to earnings reports. It details revenue and EPS figures for recent quarters, upcoming estimates for Q1 2026, and discusses the correlation between earnings revisions and stock price movements, suggesting potential buying opportunities despite recent stock price dips.
Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts
Myriad Genetics is promoting its Prequel Prenatal Screen to help healthcare providers confidently address uncertain prenatal test results. The screen aims to provide early and reliable insights, thereby minimizing delays in critical decision-making for patient management, as supported by physicians like Dr. Christian Briery. This solution is designed to enhance healthcare providers' assurance when faced with diagnostic ambiguity in prenatal care.
FDA Approves Myriad Genetics' MyChoice CDx Test for Advanced Ova
Myriad Genetics (MYGN) has received FDA approval for its MyChoice CDx Test, which will serve as a companion diagnostic for GSK's Zejula in treating advanced ovarian cancer. Despite this advancement in precision medicine, the company faces financial challenges including negative earnings and high volatility. Investors should carefully consider these financial health and market valuation concerns.
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Myriad Genetics announced FDA approval of its MyChoice CDx Test as a companion diagnostic for GSK's Zejula (niraparib) in advanced ovarian cancer patients. The test identifies homologous recombination deficient (HRD) tumors, reinforcing Myriad's leadership in ovarian cancer diagnostics. This approval ensures that treatment decisions for PARP inhibitors like Zejula are guided by precise genomic insights, as nearly 50% of advanced ovarian cancer patients have HRD-positive tumors.
Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld
Myriad Genetics' Chief Legal Officer, Jennifer Lynne Fox, was granted 195,876 time-based restricted stock units (RSUs) on March 12, 2026. These RSUs will vest in three equal annual installments. Additionally, 5,995 shares were withheld on March 13, 2026, at $4.66 per share to cover tax obligations from previously vested RSUs, bringing her direct holdings to 310,362 shares.
Myriad Genetics Receives FDA Approval of the MyChoice CDx
Myriad Genetics announced that the FDA has approved its MyChoice CDx Test as a companion diagnostic for Zejula (niraparib) in patients with advanced ovarian cancer. This approval is based on data from the PRIMA trial and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States. The test identifies homologous recombination deficiency (HRD) status, which is crucial for determining patient eligibility for PARP inhibitor therapy.
FDA approves genetic test to match ovarian cancer patients to Zejula
Myriad Genetics announced that the FDA has approved its MyChoice CDx Test as the companion diagnostic for GSK's cancer drug Zejula (niraparib) for patients with advanced ovarian cancer in the United States. This approval, based on final PRIMA trial data, establishes MyChoice CDx as the sole FDA-authorized companion diagnostic for Zejula, identifying patients with homologous recombination deficiency (HRD) positive tumors through next-generation sequencing. The test is crucial for guiding treatment decisions, as nearly half of advanced ovarian cancer patients have HRD+ tumors and can benefit from PARP inhibitors like Zejula.
Myriad Genetics (MYGN) CTO has shares withheld to cover taxes
Myriad Genetics' Chief Technology Officer, Kevin Richard Haas, reported tax-related share dispositions between March 13-15, 2026. A total of 22,310 shares of Common Stock were withheld by the company to satisfy tax obligations from vesting restricted and performance-based stock units. These transactions are not considered open-market sales, and Haas still directly holds 180,022 shares after these withholdings.
Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares
Myriad Genetics' Chief Scientific Officer, Dale Muzzey, was granted 173,196 restricted stock units (RSUs) on March 12, 2026, which vest in three equal annual installments. Concurrently, the company withheld 37,799 shares between March 13-15, 2026, at $4.66 per share, to cover tax obligations from the vesting of previous RSUs. Following these transactions, Muzzey directly holds 329,275 shares of common stock.
Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion
Myriad Genetics Inc (ISIN: US62855J1043), a molecular diagnostics and precision-medicine company, is navigating competitive pressures while focusing on growth in oncology and reproductive health testing. Despite industry-wide reimbursement headwinds, the company is positioned for long-term growth through its consumables-driven test model, installed-base expansion, and AI-enhanced interpretation tools. European investors are assessing Myriad's valuation, considering its consistent cash flow generation, moderate dividend increases, and potential for international expansion and AI-driven productivity gains.
Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax
Myriad Genetics Chief People Officer Shereen Solaiman was granted 173,196 time-based Restricted Stock Units (RSUs) on March 12, 2026, vesting in three equal annual installments. The company also withheld 14,683 shares of common stock on March 13 and 14, 2026, at a price of $4.6600, to cover tax obligations from previously vested RSUs. Following these transactions, Solaiman directly holds 267,801 shares of Myriad Genetics common stock.
Myriad Genetics receives FDA approval for ovarian cancer test
Myriad Genetics (NASDAQ: MYGN) has received FDA approval for its MyChoice CDx Test as a companion diagnostic for GSK's ovarian cancer drug, Zejula. This test is the only FDA-approved diagnostic in the U.S. for identifying patients with homologous recombination deficiency-positive status eligible for Zejula treatment. Despite this positive news, Myriad Genetics' shares have recently declined, though InvestingPro analysis suggests the stock may be undervalued.
Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs
Myriad Genetics' Chief Commercial Officer, Brian J. Donnelly, reported receiving 226,804 Restricted Stock Units (RSUs) as an equity grant. These RSUs, valued at $0.00 per share, will vest in three equal annual installments starting from the first anniversary of the grant date. Following this grant, Donnelly's direct holdings in Myriad Genetics common stock increased to 624,338 shares.
Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld
Myriad Genetics President and CEO Samraat S. Raha reported receiving a grant of 618,557 time-based Restricted Stock Units (RSUs) on March 12, 2026, which will vest in three equal annual installments. Additionally, 47,120 shares of common stock were withheld by the company on March 13 and 14, 2026, at $4.66 per share to cover tax obligations from previously vested RSUs. Following these transactions, Raha directly owns 1,064,541 shares of Myriad Genetics common stock.
Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion
Myriad Genetics Inc, a molecular diagnostics and precision-medicine platform, is at an inflection point, navigating robust demand for genetic testing against competitive pricing and reimbursement uncertainties. The company leverages a consumables-driven test model, installed-base expansion, and AI-enhanced interpretation tools to drive long-term growth, with European investors assessing its valuation amid industry consolidation. Key segments like oncology and reproductive health show promise, with potential for margin expansion through operating leverage, though risks from reimbursement cuts and competition persist.
Myriad Genetics, Inc. $MYGN Shares Sold by Anson Funds Management LP
Anson Funds Management LP significantly reduced its holdings in Myriad Genetics, selling 841,938 shares and retaining 504,382 shares. This reduction contrasts with recent insider buying activity, where Myriad Genetics CEO Samraat S. Raha and Director S. Louise Phanstiel acquired shares. Analyst sentiment for MYGN is mixed, with a consensus "Hold" rating and an average price target of $8.94, despite some analysts cutting their targets to $6.
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know
Shares of Myriad Genetics (NASDAQ:MYGN) jumped 6.9% after its President and CEO, Samraat Raha, purchased 40,000 shares for approximately $200,000, signaling strong confidence in the company. This comes after the company recently launched its Precise MRD™ test for breast cancer and reaffirmed its full-year 2026 financial outlook. Despite the recent gains, Myriad Genetics's stock is down 16% since the beginning of the year.
Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock
Myriad Genetics (NASDAQ:MYGN) CEO Samraat Raha recently purchased 40,000 shares of the company's stock for $200,000, increasing his total holdings to 493,104 shares. This transaction, disclosed in an SEC filing, occurred on March 9th at an average price of $5.00 per share. The company, which trades around $4.81, has a market cap of $449.78 million and analysts currently rate the stock as a "Hold" with an average price target of $8.94.
Insider Buying: Samraat Raha Acquires 40,000 Shares of Myriad Ge
Samraat Raha, President and CEO of Myriad Genetics Inc (MYGN), recently purchased 40,000 shares of the company, increasing his total holdings to 493,104 shares. This transaction is part of a trend of insider buying within the company, with no insider sales reported in the past year. Despite the insider confidence, Myriad Genetics shares were trading at $5, significantly below its GF Value of $17.74, leading GuruFocus to flag it as a "Possible Value Trap, Think Twice."
Raha, Myriad Genetics CEO, buys $199k in shares
Myriad Genetics CEO Samraat S. Raha purchased 40,000 shares of company stock for a total of $199,844. This insider buying occurred despite a 52.75% stock decline over the past year, with InvestingPro suggesting the stock is undervalued and analysts predicting future profitability. This transaction follows the company's recent strong fourth-quarter earnings, which surpassed analyst expectations.
Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN
Royce & Associates LP has made a new investment of $4.84 million in Myriad Genetics, acquiring 670,000 shares representing 0.72% ownership. Insider activity also shows Director S. Louise Phanstiel purchased over 50,000 shares. Despite mixed analyst ratings, with a consensus "Hold" and an average target price of $8.94, institutional investors hold a significant stake in the company.
Myriad Genetics Stock Up on New Breast Cancer MRD Test Launch | 2026 - News and Statistics
Myriad Genetics saw its stock rise following the launch of a new breast cancer monitoring test designed for molecular residual disease. The company initiated the launch with a limited number of oncology practices and plans a wider commercial release later in the year, coinciding with a presentation at a healthcare conference and reaffirmed financial outlook. This positive movement is notable given the stock's recent volatility and year-to-date decline.
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
Myriad Genetics (MYGN) stock jumped 5.9% after launching its Precise MRD™ test for breast cancer and presenting at a healthcare conference. The company also reaffirmed its full-year 2026 financial outlook, signaling confidence in its growth. Despite the recent positive news, the stock is down 14.4% since the beginning of the year and 50% below its 52-week high.
New breast cancer test detects residual disease beyond standard scans
Myriad Genetics (NASDAQ: MYGN) has launched Precise MRD, a tumor-informed circulating tumor DNA (ctDNA) test for breast cancer patients, with selected community oncologists. This test uses whole-genome sequencing to create personalized assays, enabling ultrasensitive detection of ctDNA down to one part per million, which can identify residual disease not visible through conventional imaging. Myriad plans a broader U.S. commercial launch later in 2026.
Myriad Genetics (MYGN) CPO has shares withheld to cover taxes
Myriad Genetics' Chief People Officer, Shereen Solaiman, had 1,675 shares of common stock withheld on March 1, 2026, at $4.61 per share to cover tax obligations related to vesting restricted stock units. This transaction, categorized as a tax-related share withholding rather than an open-market sale, resulted in Solaiman directly holding 109,288 shares of Myriad Genetics common stock afterward. The withholding was based on the closing price of the company's common stock on February 27, 2026.
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages
Thirteen brokerages have issued a consensus "Hold" rating for Myriad Genetics, Inc. (NASDAQ:MYGN), with an average 1-year price target of $9.17. Despite beating quarterly EPS and revenue estimates, the company remains unprofitable with a negative net margin. Recent insider buying by Director S. Louise Phanstiel indicates some confidence in the stock.
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Myriad Genetics, Inc. will release its fourth-quarter and full-year 2025 financial results on February 23, 2026, with an earnings conference call scheduled for 4:30 pm ET on the same day. Management will also participate in three investor healthcare conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Leerink Partners Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare conference. The company is a leader in molecular testing and precision medicine, focusing on genetic tests to improve patient care.
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Myriad Genetics, Inc. announced it will release its fourth quarter and full year 2025 financial results on February 23, 2026, after market close, followed by an earnings conference call at 4:30 pm ET. Management will also participate in three investor healthcare conferences in March 2026, including the TD Cowen, Leerink Partners, and Barclays conferences. The company, a leader in molecular testing and precision medicine, provides genetic tests to assess disease risk and guide treatment decisions.
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research
Zacks Research has upgraded Myriad Genetics (NASDAQ:MYGN) from a "strong sell" to a "hold" rating, aligning with an average analyst consensus and a target price of $9.17. The company surpassed quarterly earnings estimates with an EPS of $0.04 and revenue of $209.8 million, despite a negative net margin. Insider activity also showed a director acquiring 48,000 shares, increasing her stake by over 20%.
Myriad Genetics (NASDAQ: MYGN) posts Q4 2025 loss, reiterates 2026 outlook
Myriad Genetics reported a Q4 2025 revenue of $209.8 million, remaining flat year-over-year, and a GAAP net loss of $7.9 million. For the full year 2025, revenue was $824.5 million, a 2% decrease, with a significant GAAP net loss of $365.9 million largely due to goodwill and long-lived asset impairments. Despite the full-year loss, the company reaffirmed its 2026 guidance, projecting $860–$880 million in revenue and $37–$49 million in adjusted EBITDA, supported by upcoming test launches and disciplined cost management.
Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares
Myriad Genetics director S. Louise Phanstiel acquired 104,507 shares of common stock through open-market purchases over three days in late February 2026. These transactions, reported via a Form 4 SEC filing, involved purchases on February 25, 26, and 27 at weighted-average prices between $4.661 and $4.803 per share. Following these acquisitions, Phanstiel's direct ownership increased to 281,951 shares, with an additional 33,119 shares held indirectly through a trust.
Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares
Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel recently purchased 48,000 shares of the company's stock at $4.66 per share, totaling $223,680. This latest acquisition, part of a larger series of purchases, increased her direct ownership to 281,951 shares. The company reported better-than-expected quarterly EPS but still has a negative net margin, with analysts forecasting a Hold rating and an average target price of $9.17.
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 60% Upside Potential Amidst Financial Challenges
Myriad Genetics (MYGN) shows a potential 60% upside despite current financial challenges, including declining revenue growth and negative EPS. The company, engaged in molecular diagnostics, has a market capitalization of $453.02 million and an analyst target price of $7.78 against a current trading price of $4.86. Investors are faced with a mixed outlook, balancing the stock's discounted price and strategic partnerships against its bearish technical indicators and profitability concerns.
How Myriad Genetics Inc. (MYGN) Affects Rotational Strategy Timing
This article from Stock Traders Daily discusses how Myriad Genetics Inc. (NASDAQ: MYGN) influences rotational strategy timing. It presents various AI-generated trading strategies for MYGN, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The piece emphasizes the platform's ability to provide real-time entry and exit signals, risk-reward ratios, and personalized alerts to its users.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2025 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) reported Q4 2025 earnings, exceeding expectations with an EPS of $0.04 against a projected $-0.02. The company highlighted strong volume growth in MyRisk oncology tests and Prolaris, along with significant progress on its cancer care continuum strategy, including the upcoming alpha launch of Precise MRD for breast cancer. Myriad Genetics also reaffirmed its full-year 2026 financial guidance, anticipating sequential revenue growth throughout the year despite some near-term headwinds in prenatal testing.
Cancer, prenatal and mental health tests anchor Myriad (MYGN) 2025 plan
Myriad Genetics (MYGN) has outlined its 2025 business strategy, focusing on oncology, women's health, and mental health through molecular diagnostics and precision medicine. Key initiatives include expanding its Cancer Care Continuum portfolio, growing Precise MRD for molecular residual disease, and launching the FirstGene 4-in-1 prenatal screen in 2026. The company reported $824.5 million in revenue for 2025, a 2% decrease year-over-year, mainly due to changes in GeneSight coverage and the divestiture of its European EndoPredict business. Myriad plans continued R&D investment and strategic collaborations to drive profitable growth and operational efficiency while navigating competitive and regulatory challenges.
Myriad Genetics Inc files for mixed shelf of up to $200 million - SEC filing
Myriad Genetics Inc. has filed with the SEC for a mixed shelf offering of up to $200 million. This news comes amidst other developments for the company, including upcoming presentations at the 2026 Asco-Gu Conference, recent analyst target adjustments, and its latest quarterly and full-year earnings reports. Myriad Genetics is a genetic testing and precision medicine company focusing on Oncology, Women's Health, and Mental Health.
Why Myriad Genetics (MYGN) Stock Is Trading Up Today
Shares of Myriad Genetics (MYGN) rose 4.9% after the company reported better-than-expected fourth-quarter 2025 earnings, surpassing analyst forecasts for both revenue and profit. The company posted an adjusted profit of $0.04 per share against a forecasted loss, and its adjusted EBITDA more than doubled expectations. Despite flat quarterly revenue year-on-year, strong profitability and positive full-year EBITDA guidance drove investor optimism.
